MedTrace Logo

A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507

NCT02597465 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2020-12-14

No results posted yet for this study

Summary

An open label study to determine the efficacy and safety of SPARC1507

Conditions

  • Advanced Biliary Tract Cancer

Interventions

DRUG

SPARC1507

The administered dose is calculated based on the BSA calculated for the subject on Day 1 of the Cycle

DRUG

Reference1507

Investigators choice including chemotherapy or supportive therapy

Sponsors & Collaborators

  • Sun Pharma Advanced Research Company Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2019-03-01
Completion
2019-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02597465 on ClinicalTrials.gov